Abstract
A series of novel substituted-[(3R)-amino-2-(2,5-difluorophenyl)]tetrahydro-2H-pyran analogs have been prepared and evaluated as potent, selective and orally active DPP-4 inhibitors. These efforts lead to the discovery of a long acting DPP-4 inhibitor, omarigliptin (MK-3102), which recently completed phase III clinical development and has been approved in Japan.
Keywords:
DPP-4 inhibitor; DPP-8; DPP-9; Omarigliptin; Pyrazolopyrolidine; Sitagliptin; Type 2 diabetes; X-ray.
Copyright © 2015 Elsevier Ltd. All rights reserved.
MeSH terms
-
Amides / chemistry*
-
Animals
-
Binding Sites
-
Dipeptidyl Peptidase 4 / chemistry
-
Dipeptidyl Peptidase 4 / metabolism
-
Dipeptidyl-Peptidase IV Inhibitors / chemical synthesis
-
Dipeptidyl-Peptidase IV Inhibitors / chemistry*
-
Dipeptidyl-Peptidase IV Inhibitors / pharmacokinetics
-
Dogs
-
Half-Life
-
Heterocyclic Compounds, 2-Ring / chemical synthesis
-
Heterocyclic Compounds, 2-Ring / chemistry*
-
Heterocyclic Compounds, 2-Ring / pharmacokinetics
-
Molecular Docking Simulation
-
Protein Structure, Tertiary
-
Pyrans / chemical synthesis
-
Pyrans / chemistry*
-
Pyrans / pharmacokinetics
-
Rats
-
Structure-Activity Relationship
-
Sulfonamides / chemistry*
Substances
-
2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine
-
Amides
-
Dipeptidyl-Peptidase IV Inhibitors
-
Heterocyclic Compounds, 2-Ring
-
Pyrans
-
Sulfonamides
-
Dipeptidyl Peptidase 4